Cindy Lee, Pharm D
About Cindy Lee, Pharm D
Cindy Lee, Pharm D, is the Head of Worldwide Medical - Early Transition Oncology at Bristol Myers Squibb, with extensive experience in managing medical strategy and communications in Immuno-Oncology.
Company
Cindy Lee currently holds the position of Head, Worldwide Medical - Early Transition Oncology at Bristol Myers Squibb in Princeton, New Jersey, United States. Bristol Myers Squibb is known for its strong focus on oncology and its commitment to advancing cancer treatment through innovative research and therapies.
Title
Cindy Lee serves as the Head, Worldwide Medical - Early Transition Oncology, where she plays a critical role in overseeing the transition of oncology therapies from early development to clinical practice. Her responsibilities include managing medical strategy and communications, specifically in the field of Immuno-Oncology.
Education and Expertise
Cindy Lee earned her PharmD from Rutgers University, where she studied from 1996 to 2002. She has extensive expertise in managing medical strategy and communications in Immuno-Oncology and has a demonstrated history of working in early and late-stage oncology drug development. Her skills also include training and developing medical professionals in the oncology sector.
Background
Before her current role, Cindy Lee has a long history of positions at Bristol Myers Squibb. These roles include HQ Medical Lead, Immuno-Oncology, Head & Neck and Glioblastoma (2018-2020), Lymphoma Medical Scientist, US Medical Oncology (2015-2017), Associate Director, Medical Information-Oncology (2012-2015), and Sr. Manager, Medical Information-Oncology (2007-2012). Prior to joining Bristol Myers Squibb, she worked at Embryon and Medical Action Communications, holding roles such as Medical Writer and Associate Scientific Director.
Achievements
Cindy Lee has a proven track record in medical information dissemination and education within the oncology community. She has been notably involved in the transition of oncology therapies from early development to clinical practice, highlighting her expertise in the field. Her extensive experience in managing medical strategies in Immuno-Oncology demonstrates her strong background and impact within the sector.